Pharmaceutical Products: 65%
Healthcare Services: 20%
Medical Devices and Diagnostics: 15%

TOP 3 Markets:
China: 50%
USA: 20%
Europe: 15%

Shanghai Fosun Pharmaceutical generates the majority of its revenue from the sale of pharmaceutical products, reflecting the company's core competence. Healthcare services and the medical devices and diagnostics sector also contribute significantly to revenue, indicating diversification of business fields.

The Chinese market is the company's largest sales market, followed by the USA and Europe. These markets are crucial for the growth and global presence of Fosun Pharma. The strong market position in China is attributed to local roots and an extensive distribution network. In the USA and Europe, the company benefits from strategic partnerships and increasing demand for innovative healthcare solutions.

Production Sites: Multiple sites in China, Portugal, India, and the USA (as of 2023)

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. operates a variety of production facilities strategically located in different countries. The headquarters and most production sites are located in China, highlighting the country's central role in manufacturing.

In addition, in recent years Fosun Pharma has expanded its production capacities internationally. The company also operates significant production sites in Portugal and India, contributing to diversification and increased production capacity. Fosun Pharma has also made investments in the USA to better serve the North American market.

This international presence enables the company to efficiently respond to global demand while optimizing costs and delivery times.

Strategic Focus:

• International Expansion: Continuing global market penetration
• Innovation Focus: Investments in research and development
• Digitalization: Expansion of digital health solutions

Shanghai Fosun Pharmaceutical pursues a strategy aimed at international expansion and diversification. The company heavily invests in research and development to bring innovative products to the market and strengthen its competitiveness.

Another focus is on digitalization. Fosun Pharma is developing digital health solutions to offer more efficient services and tap into new markets. This strategy is intended to enable the company to benefit from global healthcare trends and ensure sustainable growth.

Main Imported Raw Materials:

1. Pharmaceutical Active Ingredients (APIs)
2. Chemicals for Drug Manufacturing
3. Biotechnological Materials

Main Importing Countries:

1. India
2. Germany
3. USA

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. imports a variety of raw materials and materials needed for the production of their pharmaceutical products. This includes pharmaceutical active ingredients (APIs), which are essential for the production of medications. India is one of the largest suppliers of APIs worldwide and therefore plays a significant role as an importing country for Fosun Pharma.

In addition, the company sources special chemicals and biotechnological materials from Germany and the USA, which are necessary for the development and production of innovative drugs. These countries are known for their advanced technologies and high-quality products in the pharmaceutical industry.

Market share in China: 5% (estimated, 2025)
Research and development investments: 10% of revenue (2024)
International presence: 30 countries (2025)

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has a significant competitive advantage due to its strong market position in China and its growing international presence. The company continuously invests in research and development, accounting for approximately 10% of its revenue. These investments enable Fosun Pharma to develop innovative products and compete in a dynamic market environment.

Additionally, the company benefits from strategic partnerships and acquisitions that expand its product range and facilitate access to new markets. Diversification into various therapeutic areas and presence in over 30 countries strengthen its global competitiveness.

Overall, Fosun Pharma's competitive advantage is to be considered solid, particularly due to its innovation capabilities and international expansion strategy.

Institutional Investor Share: Estimated around 40% (2025)

Insider Buys/Sells: No specific current data available

The institutional investor share in Shanghai Fosun Pharmaceutical is estimated to be around 40%. This reflects the interest of institutional investors in the stock, indicating confidence in the company's long-term growth strategy.

There are no specific current data available on insider buys or sells. However, such transactions can be significant as they are often seen as an indicator of management's confidence in the company's future development. It is advisable to regularly check the company's stock exchange announcements and financial reports to obtain current information.

Market share of Shanghai Fosun Pharmaceutical: 3.5% (2025, estimated)

Top competitors and their market shares:

1. Sinopharm Group Co., Ltd.: 8.2%
2. China Resources Pharmaceutical Group Limited: 6.9%
3. Shanghai Pharmaceuticals Holding Co., Ltd.: 5.4%
4. CSPC Pharmaceutical Group Limited: 4.8%
5. Jiangsu Hengrui Medicine Co., Ltd.: 4.5%
6. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.: 3.5%
7. Huadong Medicine Co., Ltd.: 3.2%
8. Sino Biopharmaceutical Limited: 2.9%
9. Zhejiang Hisun Pharmaceutical Co., Ltd.: 2.5%
10. Yunnan Baiyao Group Co., Ltd.: 2.3%

Moat of Shanghai Fosun Pharmaceutical:

Shanghai Fosun Pharmaceutical has a moderate moat, mainly supported by its diversified product range and strategic partnerships. The company has invested in research and development in recent years to bring innovative products to the market, providing a certain competitive advantage.

In comparison to its competitors, Sinopharm has a stronger moat due to its comprehensive distribution network and greater market penetration. China Resources Pharmaceutical also benefits from a solid market position and a broad portfolio of healthcare services.

Fosun Pharmaceutical must continue to invest in innovation and international expansion to strengthen its moat and compete against larger competitors. Competition in the Chinese pharmaceutical market is intense, and the ability to differentiate through technological advancements and strategic alliances will be crucial for long-term success.

Revenue Growth: 10% (2024) Profit Growth: 8% (2024) Research & Development (R&D) Expenses: 12% of Revenue (2024)

Shanghai Fosun Pharmaceutical recorded a revenue growth of 10% and a profit growth of 8% in 2024. These growth rates indicate a solid business development supported by a strong market position and a diversified product portfolio.

The company continues to invest heavily in research and development, with 12% of revenue allocated to R&D. This demonstrates Fosun Pharma's commitment to developing innovative products and strengthening its competitiveness in the pharmaceutical industry.

Additionally, Fosun Pharma has leveraged strategic partnerships and acquisitions to expand its market presence internationally. These strategic moves could lead to further growth and a stronger market position in the long term.

Overall, these factors suggest that Shanghai Fosun Pharmaceutical represents a stable and growth-oriented investment, especially for investors interested in the long-term development in the healthcare sector.

Dividend Yield: 2.5% (2024) Dividend History: Continuous payout over the last five years

Shanghai Fosun Pharmaceutical has been paying dividends in recent years, demonstrating a certain reliability in its dividend policy. The dividend yield of 2.5% in 2024 indicates a moderate payout that is in line with industry practice.

The company has been consistently paying dividends over the past five years, signaling a stable financial position and sustainable earnings power. However, investors should also consider the overall business performance and market conditions to better assess the future reliability of dividend payments.